Samsara BioCapital

Samsara BioCapital is a prominent venture capital firm based in Palo Alto, United States, dedicated to investing in and building next-generation biotechnology companies. Established with a clear focus on the life sciences sector, Samsara BioCapital seeks to partner with entrepreneurs who are developing novel therapeutics to address significant unmet medical needs across various disease areas, including oncology, neuroscience, and rare diseases. The firm leverages the deep scientific and operational expertise of its team to support its portfolio companies from inception through commercialization.

Samsara BioCapital employs a flexible investment strategy, deploying capital across all stages of development, from company formation and seed rounds to late-stage private and even public companies. The firm often takes on lead or co-lead investor roles in funding rounds, demonstrating its commitment to its portfolio companies and its confidence in their potential. This hands-on approach, combined with substantial financial backing, positions Samsara BioCapital as a key enabler of innovation in the biotech industry.

The firm has demonstrated significant fundraising success, which underpins its capacity for substantial investments. Samsara BioCapital Fund I, L.P., closed in 2017 with $230 million, followed by Samsara BioCapital Fund II, L.P., which raised $410 million in 2021. These significant fund sizes enable the firm to make meaningful initial investments and provide follow-on capital to support the long and capital-intensive development cycles characteristic of biotechnology. Their typical first check sizes reflect this capacity, ranging from early-stage commitments to leading substantial growth rounds.